This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
The Scalability Challenge in MSC Therapies
John Yoshi Shyu on why mesenchymal stem cell programs stall – and how early manufacturing decisions can determine clinical and commercial success
06/12/2026
4 min read
Interview
